Over the forecast period, rising kidney disease incidence is anticipated to fuel the growth of the global ureteral stents market. The global ureteral stents market is anticipated to rise over the forecast period due to an increase in product approvals by regulatory bodies. The ureteral stents market's manufacturers are working on new products and technical advancements, which is anticipated to fuel market growth. Additionally, one of the main factors propelling market growth is doctors' increased focus on minimally invasive ureteral stricture treatment. For temporary internal drainage from the ureter pelvic junction to the bladder, Cook Medical's C-Flex Double Pigtail Ureteral Stent product is used. Boston Scientific, Olympus Medical Corporation, SILMAG, UROMED, Coloplast Ltd., and C.R. Bard are a few of the major companies that provide pigtail stents. The global ureteral stents market is expanding rapidly as a result of an increasing number of product advancements and a focus on product enhancement. Over the forecast period, the global ureteral stents market is anticipated to grow as a result of increased ureteral stent research and development.
Coherent Market Insights estimates that the market for Ureteral stents is projected to reach US$ 498.2 million in 2022 and is predicted to grow at a CAGR of 5.6% from 2022 to 2030.
Leading Companies in the Ureteral Stents Industry:
1. BD
The company was founded in 1897 and is based in New Jersey, U.S. The company manufactures and sells reagents, instrumentation, and medical gear. Additionally, in some regions, BD offers consulting and analytics offerings. To improve first-stick success rates for IV insertions, BD will launch advanced ultrasound technology in April 2023. In Tijuana, BD launched a new $38.6 million manufacturing facility for medication management in November 2022.
2. Boston Scientific Corporation
The company was established in 1979 and has its headquarters in Marlborough, Massachusetts, in the United States. The company designs, fabricates, and markets minimally invasive medical equipment. Boston announced in January 2021 that it would spend up to $1.2 billion to purchase Minneapolis-based Preventice Solutions, Inc. and its portfolio of mobile heart health solutions. The business disclosed its intentions to acquire M.I.Tech Co., Ltd. of South Korea for roughly $230 million in June 2022. Boston declared in August 2022 that it will purchase Obsidio, Inc.
